Paloma Partners’s AbbVie ABBV Stock Holding History

Paloma Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,775	Closed	-$1.21M	–	99
2025 Q1	$1.21M	Buy	+5,775	New	+$1.12M	0.15%	77
2024 Q4	–	Sell	-2,895	Closed	-$572K	–	274
2024 Q3	$572K	Sell	2,895 -11,807	-80%	-$2.2M	0.02%	585
2024 Q2	$2.52M	Buy	14,702 +14,243	+3,103%	+$2.36M	0.07%	298
2024 Q1	$83.6K	Sell	459 -2,119	-82%	-$365K	﹤0.01%	670
2023 Q4	$400K	Buy	+2,578	New	+$376K	0.01%	560
2023 Q3	–	Sell	-875	Closed	-$118K	–	702
2023 Q2	$118K	Buy	875 +728	+495%	+$107K	﹤0.01%	641
2023 Q1	$23.4K	Buy	+147	New	+$22.5K	﹤0.01%	718
2022 Q4	–	Sell	-200	Closed	-$30.7K	–	887
2022 Q3	$27K	Buy	+200	New	+$28.7K	﹤0.01%	920
2022 Q1	–	Sell	-29,973	Closed	-$4.35M	–	1714
2021 Q4	$4.06M	Buy	29,973 +24,889	+490%	+$2.94M	0.06%	262
2021 Q3	$548K	Sell	5,084 -2,057	-29%	-$235K	0.01%	512
2021 Q2	$804K	Sell	7,141 -14,130	-66%	-$1.59M	0.01%	747
2021 Q1	$2.3M	Buy	21,271 +19,341	+1,002%	+$2.07M	0.05%	361
2020 Q4	$207K	Sell	1,930 -12,431	-87%	-$1.19M	0.01%	1371
2020 Q3	$1.26M	Buy	14,361 +12,864	+859%	+$1.21M	0.03%	606
2020 Q2	$147K	Sell	1,497 -14,447	-91%	-$1.27M	﹤0.01%	1804
2020 Q1	$1.21M	Buy	15,944 +6,040	+61%	+$514K	0.07%	240
2019 Q4	$877K	Buy	9,904 +4,850	+96%	+$403K	0.01%	1023
2019 Q3	$383K	Sell	5,054 -165,203	-97%	-$11.3M	0.01%	1365
2019 Q2	$12.4M	Buy	170,257 +73,066	+75%	+$5.74M	0.21%	77
2019 Q1	$7.83M	Buy	+97,191	New	+$7.95M	0.19%	93
2018 Q4	–	Sell	-182,555	Closed	-$17.3M	–	1218
2018 Q3	$17.3M	Sell	182,555 -97,803	-35%	-$9.27M	0.31%	50
2018 Q2	$26M	Buy	280,358 +240,141	+597%	+$23.5M	0.47%	20
2018 Q1	$3.81M	Buy	+40,217	New	+$4.42M	0.06%	279
2017 Q3	–	Sell	-22,585	Closed	-$1.72M	–	2058
2017 Q2	$1.64M	Sell	22,585 -67,422	-75%	-$4.53M	0.02%	887
2017 Q1	$5.87M	Buy	90,007 +66,958	+291%	+$4.21M	0.07%	256
2016 Q4	$1.44M	Sell	23,049 -9,905	-30%	-$605K	0.01%	910
2016 Q3	$2.08M	Sell	32,954 -13,136	-29%	-$850K	0.03%	531
2016 Q2	$2.85M	Sell	46,090 -30,760	-40%	-$1.87M	0.03%	499
2016 Q1	$4.39M	Buy	76,850 +70,150	+1,047%	+$3.91M	0.07%	212
2015 Q4	$397K	Sell	6,700 -194,692	-97%	-$11.2M	0.01%	1172
2015 Q3	$11M	Buy	201,392 +189,945	+1,659%	+$12.4M	0.25%	52
2015 Q2	$769K	Sell	11,447 -1,067	-9%	-$69.7K	0.01%	888
2015 Q1	$733K	Sell	12,514 -32,592	-72%	-$1.97M	0.02%	624
2014 Q4	$2.95M	Buy	45,106 +39,789	+748%	+$2.51M	0.13%	164
2014 Q3	$307K	Buy	+5,317	New	+$295K	0.01%	701

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Paloma Partners's ABBV Position: Q2 2025 in Review

Paloma Partners sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 5,775 shares — an estimated $1.21M sold.

Paloma Partners first reported a position in ABBV in Q3 2014 and held it in 35 quarters. The position peaked at $26M in Q2 2018. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Paloma Partners reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Paloma Partners sold 5,775 AbbVie shares in Q2 2025, an estimated $1.21M.
Paloma Partners first reported a position in AbbVie in Q3 2014 and held it in 35 quarters.
Paloma Partners's AbbVie position peaked at $26M in Q2 2018.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.